New Distribution Agreement Signed

30 January 2018

AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

New Distribution Agreement Signed

Completing Lojuxta Footprint in Eastern Europe

Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has signed an exclusive distribution agreement for Lojuxta® (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL ("Romastru"), a Bucharest-based pharmaceutical services company, part of Pharaon Healthcare Europe, a conglomerate which provides a wide range of services, including medical, marketing research, storage and distribution.

This is the fourth distribution agreement signed by Amryt in the last three months, and it broadens further the Company's distribution footprint for Lojuxta in Central and Eastern Europe. The Company aims to complete further agreements across its in-licenced territories in Europe, Middle East and Africa as the year progresses.

Lojuxta is a treatment for Homozygous Familial Hypercholesterolemia ("HoFH"), the rare, life-threatening, genetic cholesterol disorder, and Amryt estimates that there are approximately 30 patients with HoFH in Romania and Bulgaria combined.

Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said:

"We are pleased to have signed this agreement with Romastru, a long-established pharmaceutical services company based in Bucharest. Romastru's reach across Romania and Bulgaria means that we can now provide comprehensive access to Lojuxta for adult patients suffering from HoFH in these territories."

Enquiries:

About Amryt Pharma plc

(www.amrytpharma.com)

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. 

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.